Adenosine A_2A Receptors Modulate Acute Injury and Neuroinflammation in Brain Ischemia

Table 2

Effect of A_2A receptor agonist, CGS21680, in acute and delayed phase of stroke.

Drug	24 h after pMCAo		7 days after tMCAo
	Infarct volume (mm^3)		Treatment	Infarct volume (mm^3)
	Cortex	Striatum		Cortex	Striatum
Vehicle	69.43 ± 1.87	46.03 ± 2.7	Subchronic	75.1 ± 5.1	28.4 ± 2.2
			Chronic	76.2 ± 4.3	31.3 ± 2.6
CGS21680	61.37 ± 8.26	45.68 ± 2.6	Subchronic 0.1	62.7 ± 5.8	30.5 ± 2.5
			Chronic 0.1	48.6 ± 9.5^#	27.3 ± 1.7
			Chronic 0.01	51.9 ± 10.4^#	20.9 ± 3.8

Data are the mean ± S.E.M. of 𝑛 = 6–8 animals. In the model of permanent MCAo (pMCAo), CGS21680 was administered at the dose of 0.1 mg/kg (i.p.) after 4 h and 20 h from ischemia induction. The infarct volume was evaluated 24 h thereafter.
In the model of transient MCAo (tMCAo), CGS21680 was administered in subchronic protocol 4 h and 20 h after ischemia at the dose of 0.1 mg/kg (i.p.) and in chronic protocol starting 4 h after ischemia, at the dose of 0.01 or 0.1 mg/kg (i.p.), twice/day for 7 days. The infarct volume was evaluated 7 days after MCAo.
One-way ANOVA: ^#𝑃<0.05 versus chronic vehicle-treated rats.
Effects of CGS21680 chronically administered are published [46].